Condition: Non-Small Cell Lung Cancer · Colorectal Cancer · Pancreatic Cancer · Sponsor: Gritstone bio, Inc.
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. Based on the Phase 1 data, an updated vaccine candidate (SLATE-KRAS or version 2) was developed that removed 16 of the 20 mutations included in the original vaccine (version 1) and solely targets KRAS mutations.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | — |
| UCLA Medical Center | Santa Monica, California, United States | — |
| Mayo Clinic Florida | Jacksonville, Florida, United States | — |
| University of Chicago Medicine, Comprehensive Cancer Center | Chicago, Illinois, United States | — |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | — |
| Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | — |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | — |
| Tennessee Oncology | Nashville, Tennessee, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03953235